Related references
Note: Only part of the references are listed.Further evidence of clinical benefit associated with participation in phase I oncology trials
M. Markman
BRITISH JOURNAL OF CANCER (2008)
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
H-T Arkenau et al.
BRITISH JOURNAL OF CANCER (2008)
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials
Christopher K. Daugherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
A. Italiano et al.
ANNALS OF ONCOLOGY (2008)
Progression-free survival is a surrogate for survival in advanced colorectal cancer
Marc Buyse et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy
Patricia A. Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Risks and benefits associated with novel phase 1 oncology trial designs
Shlomo A. Koyfman et al.
CANCER (2007)
Patients' decision-making process regarding participation in phase I oncology research
Manish Agrawal et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis
Kent R. Johnson et al.
LANCET ONCOLOGY (2006)
Therapeutic misconception in early phase gene transfer trials
GE Henderson et al.
SOCIAL SCIENCE & MEDICINE (2006)
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
Mark J. Ratain et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
P Bruzzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Risks and benefits of phase 1 oncology trials, 1991 through 2002
E Horstmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Communication and miscommunication in informed consent to research
P Sankar
MEDICAL ANTHROPOLOGY QUARTERLY (2004)
Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?
TD Shanafelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Ethics of phase 1 oncology studies - Reexamining the arguments and data
M Agrawal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials
KP Weinfurt et al.
CANCER (2003)
End points and United States food and drug administration approval of oncology drugs
JR Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Defining and describing benefit appropriately in clinical trials
NMP King
JOURNAL OF LAW MEDICINE & ETHICS (2000)
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
M Buyse et al.
LANCET (2000)
Phase I cancer trials -: A collusion of misunderstanding
M Miller
HASTINGS CENTER REPORT (2000)
What makes clinical research ethical?
EJ Emanuel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
